Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
The supplemental application for Toripalimab plus chemotherapy as perioperative treatment for resectable stage Ⅱ-Ⅲ NSCLC has been accepted by the NMPA.
-
Junshi Biosciences and Fosun Wanbang will cooperate on the development and commercialization of roconkibart in the Greater China Region.
-
NEOTORCH has finished its final analysis and met all the primary endpoints of EFS and MPR rate in the stage Ⅱ-Ⅲ NSCLC patients.
-
Junshi Biosciences announced its financial results for the full year of 2025 and provided corporate updates.
-
Jointly evaluate the synergistic therapeutic potential of JS207 (PD-1/VEGF BsAb) and ATG-037 (oral small-molecule CD73 inhibitor)
-
FDA has approved Junshi Biosciences' IND for a Phase 2/3 clinical study of JS207 (PD-1/VEGF), for the neoadjuvant treatment of NSCLC